XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

1 drugs compound snack makers' woes



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>LIVE MARKETS-GLP-1 drugs compound snack makers' woes</title></head><body>

Major U.S. indexes modestly red; Dow off ~0.4%

Cons disc weakest S&P sector; Energy leads gainers

Euro STOXX 600 index up ~0.2%

Dollar ~flat; gold slips; crude, bitcoin both up >2

U.S. 10-Year Treasury yield rises to ~4.03%

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

GLP-1 DRUGS COMPOUND SNACK MAKERS' WOES

Packaged food makers such as Hershey HSY.N face a greater threat from weight-loss drugs than anticipated, with usage on the rise, helped by online health platforms offering compounded GLP-1 weight-loss injections, analysts at Bernstein noted.

With branded GLP-1 drugs from Novo Nordisk and Eli Lilly short in supply, demand for custom-made weight-loss treatments created by combining, mixing, or altering drug ingredients has soared, and could be reaching a larger number of GLP-1 patients than captured in official data, Bernstein said.

Patterns of food consumption pointed to weakness for sweet snacks and fast food, and strength for healthier items such as soup, cottage cheese and Greek yogurt, which are consistent with the eating habits of GLP-1 patients, Bernstein noted.

The brokerage downgraded chocolate maker Hershey to "market-perform," on risks that volume recovery may be more sluggish than expected due to GLP-1 headwinds, while raising soup maker Campbell to "outperform."

U.S. telehealth company Hims & Hers Health HIMS.N began selling compounded GLP-1 medications in May. The company said in August, that the program had about 100,000 subscribers.

Vitamin Shoppe also provided access to weight-loss medication through its telehealth service, while retailer Costco Wholesale offered its roughly 130 million members access to weight-loss programs this year.

The S&P 500 Packaged Foods & Meats .SPLRCFOOD has risen 2.6% so far this year, lagging a 14% rise in the consumer staples index .SPLRCS, and a 20% rise in the S&P 500 .SPX index.


(Juveria Tabassum)

*****



FOR MONDAY'S EARLIER LIVE MARKETS POSTS:


PAYROLLS HANGOVER: GEOPOLITICS, UNCERTAINTIES WEIGH ON RISK APPETITE - CLICK HERE


CRUDE OIL FUTURES HEATING UP ON THE CHARTS - CLICK HERE


U.S. ELECTION: PREPARE FOR UNCERTAINTY AND VOLATILITY - CLICK HERE


REAL ESTATE TOUR: WARMING UP TO OFFICES - CLICK HERE


RISING YIELDS WEIGH, BANKS EDGE UP - CLICK HERE


EUROPEAN FUTURES INCH HIGHER - CLICK HERE


US 'NO LANDING' SCENARIO LIFTS MARKETS - CLICK HERE



</body></html>

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.